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Abstract Sporadic late onset cerebellar ataxia is a well-
described clinical presentation with a broad differential
diagnosis that adult neurologists should be familiar with.
However, despite extensive clinical investigations, an ac-
quired cause is identified in only a minority of cases.
Thereafter, an underlying genetic basis is often considered,
even in those without a family history. Here we apply whole
exome sequencing to a cohort of 12 patients with late onset
cerebellar ataxia. We show that 33 % of ‘idiopathic’ cases
harbor compound heterozygous mutations in known ataxia
genes, including genes not included on multi-gene panels,
or primarily associated with an ataxic presentation.
Keywords Ataxia  Whole exome sequencing  Next
generation sequencing  Diagnosis
Introduction
Adult onset cerebellar ataxia poses a considerable diag-
nostic challenge. Initial investigations focus on detecting
degenerative, toxic, structural and inflammatory etiologies
which together underlie around a third of cases [1].
Thereafter, molecular investigations for a monogenic basis
of disease are often undertaken despite 80 % of patients
having no relevant family history [2].
Current molecular investigations for sporadic cases echo
that of familial forms, beginning with testing for trinu-
cleotide repeat disorders, such as the spinocerebellar
ataxias (SCA1, 2, 3, 6, 7 and 17), dentatorubral palli-
doluysian atrophy (DRPLA) and Friedreich’s ataxia (FDR)
in most centres [1]. However, this approach fails to identify
a molecular diagnosis in 87–98 % of late onset sporadic
cases [1, 3], and subsequent investigations are undertaken
on a gene-by-gene basis, often at considerable time and
expense.
The difficulty in establishing monogenic forms of dis-
ease using this approach is increasingly challenging given
that at least 60 causative ataxia genes are reported [4].
Recent studies have therefore utilized next generation se-
quencing focusing on infantile or juvenile onset cases [5],
or adult onset ataxia with a demonstrable family history
[4]. Only two studies have described sub-sets of patients
with sporadic onset adult disease, despite it being a major
form of ataxia, and suggested that a molecular diagnosis
can be reached in *10 % of cases [4, 6]. Given this, we
applied whole exome sequencing to a cohort of individuals
with sporadic late onset ataxia.
Methods
Unrelated individuals with sporadic ataxia beginning at
30 years of age or over were identified from routine re-
ferrals to our regional neurogenetic service, in Newcastle
upon Tyne, England.
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Acquired causes of ataxia were excluded and all par-
ticipants had negative genetic testing for SCA 1, 2, 3, 6, 7,
17, DRPLA and Friedreich’s Ataxia (FA). In addition, all
adult males had negative FMR1 testing.
Blood genomic DNA was fragmented, exome enriched
and sequenced (Nextera Rapid Exome Capture 37 Mb and
HiSeq 2000, 100 bp paired-end reads). In-house bioinfor-
matic analysis included alignment to UCSC hg19, using
BWA as aligner and GATK to detect SNV and INDELS
across all samples using standard filtering parameters ac-
cording to GATK Best Practise Recommendations [7] (see
supplementary methods). Further analysis was performed
on variants with a minor allele frequency\0.005 in several
reference databases and 302 unrelated in-house controls
(see supplementary methods). Rare heterozygous, ho-
mozygous and compound heterozygous variants were de-
fined, and protein altering and/or putative ‘disease causing’
mutations as predicted by at least three out of four software
programmes were included. Pathogenicity was defined in
accordance with American College of Medical Genetic
guidelines (see supplementary methods). Genes known or
suggested to cause ataxia as a primary or secondary phe-
notype in humans from two suggested clinical panels [4, 8]
together with additional genes in which ataxia may result
as part of the phenotype (list-supplementary methods) were
assessed for variants according to the above criteria, and
confirmed by Sanger sequencing (supplementary methods).
Variants were defined using a priori criteria: (1) con-
firmed pathogenic: dominant disorders—variant previously
shown to cause ataxia in humans; recessive disorders—
either 2 variants previously shown to cause ataxia in hu-
mans; or 1 pathogenic variant with a second variant pre-
dicted to affect protein function by at least 3 of 4 prediction
algorithms (SIFT, Polyphen2, Mutation Taster, LRT), or
through frameshift or truncation. (2) Probable pathogenic:
dominant and recessive disorders—variants in known ge-
nes causing ataxia in humans and predicted to affect pro-
tein function by at least three of four prediction algorithms;
(3) uncertain significance: dominant and recessive disor-
ders—variants predicted to affect protein function with
weak evidence that gene alteration causes ataxia in
humans.
The study was granted ethical approval from a Research
Ethics Committee based in the North of England.
Results
Population
Twelve Caucasian individuals of British origin (5 male)
with no known consanguinity were included (Table 1).
Mean age at disease onset was 46.7 years (SD 11; range
30–70 years). Mean disease duration was 16.6 years (SD
6.9; range 6–30 years). For one patient, the disease dura-
tion fell within the range expected for multi-system atrophy
[9]. This patient had a normal DaTscan and autonomic
function tests. Three individuals had CSF examination with
negative oligoclonal bands. Five had nerve conduction
studies; two of which were abnormal. Detailed clinical
features and the results of clinical investigations are shown
in Table 1.
Diagnosis
We identified previously described pathogenic mutations in
four of the 12 (33 %) patients in our cohort. All were
present on confirmatory Sanger sequencing. No probable
pathogenic variants were identified and variants of uncer-
tain significance were found in an additional two cases
(17 %). Findings are summarised in Table 2.
Discussion
We identified confirmed or probable pathogenic variants
causing sporadic late onset ataxia in four patients (33 %) in
our cohort. These findings are comparable to childhood/
adolescent ataxia using targeted sequencing panels (40 %)
[4] and whole exome sequencing (27 %) [5]. They are also
significantly higher than previous data for adult onset cases
using either panels or whole exome (both *10 %) [4, 6].
We detected pathogenic variants in SPG7, SYNE1 and
ANO10 (previously published by Balreira et al. [10]). Fogel
et al. [6] also identified pathogenic variants in these genes
(SPG7 (n = 2), SYNE1 (n = 3) and ANO10 (n = 1). The
clinical features of these patients appear relatively ho-
mogenous between their and our study, with pure cere-
bellar ataxia beginning above the age of 40 for ANO10 and
SYNE1 cases, and a more heterogeneous age of onset
(\20–50) with additional neurological features including
spasticity and a polyneuropathy in SPG7 cases [6].
Therefore, pathogenic mutations in these genes appear to
be an important and frequently identified cause of late
onset sporadic ataxia.
We used whole exome sequencing (WES) rather than
targeted next generation ‘panels’, and it remains a con-
tentious issue as to which is more appropriate in the inves-
tigation of neurogenetic disorders. WES enables greater
genome coverage, and hence detection of pathogenic muta-
tions in genes not considered as having ataxia as a primary
phenotype. Our results highlight this as SPG7 was not cov-
ered by one ataxia panel [4], SYNE1 by another [8], and
ANO10 was not included in either panel. WES however, may
result in detection of unexpected findings such as pathogenic
mutations predisposing to cancer or neurodegenerative
J Neurol (2015) 262:1822–1827 1823
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disease, which must be considered and included in appro-
priate consent procedures. It must also be noted that neither
WES nor targeted panels are appropriate to screen for ge-
nomic rearrangements or trinucleotide repeat sequences.
Determining pathogenicity can be challenging for
heterozygous variants without a family history of disease
and additional living family relatives for segregation ana-
lysis. In our cohort, we found heterozygous variants in
SLC33A1 and PLEKHG4 in single cases (Table 2).
Heterozygous mutations in SLC33A1 have been associated
with spastic paraplegia (SPG42) with ataxia in a single
family, and likewise, missense mutations in PLEKHG4 have
been implicated in dominant late onset forms of spinocere-
bellar ataxia in Japanese individuals. Despite the rarity and
putative pathogenicity of the variants in our patients, the
lack of data to test segregation makes attributing patho-
genicity difficult. As NGS begins to develop larger variant
datasets in rare diseases it is vital to share such data through
collaborative projects which may aid pathogenicity confir-
mation through the identification of the same or related
variants in unrelated families with a similar phenotype.
In conclusion, we have demonstrated that application of
WES to a cohort of unrelated individuals following ex-
clusion of common trinucleotide repeat disorders estab-
lishes a molecular cause of disease in a third of cases.
These findings have significant implications for clinical
practise.
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